Longboard Pharmaceuticals
在场
是其中之一......
Longboard Pharmaceuticals 是一家在股票代码 LBPH (US) 下上市的公司。
涉及Longboard Pharmaceuticals的并购和融资。
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
高管
查看带有其 21 名主要高管的组织结构图
Longboard Pharmaceuticals 搜索最多的简介
- Kevin Lind, Director, President and Chief Executive Officer
- Phillip Schneider, Director
- Vincent Aurentz, Director
创建提醒
跟踪 Longboard Pharmaceuticals 的高管变动
药店
Longboard Pharmaceuticals 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Longboard Pharmaceuticals 的最新新闻稿
- Press Releases | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference | Longboard Pharmaceuticals
- Press Releases | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15 | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Participate in Upcoming Investor Events | Longboard Pharmaceuticals
- Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021 | Longboard Pharmaceuticals
- Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial | Longboard Pharmaceuticals
- Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences | Longboard Pharmaceuticals
- View more press releases Close
通过电子邮件
